SMARCA4 and cancer: The loss of BRG1 in various human cancers, including nearly all SMARCA4-DTS and SCCOHT cancers and at least 10% of NSCLC cancers, which often have a typical, poorly differentiated rhabdoid morphology and highly aggressive clinical features [4,5,6,7,8], supports this premise.